Emerging drugs for cancer cachexia

Bibliography

• WARREN S: The inmediate cause of death in cancer. Am. J. Med. Sci. (1932) 184:610-613.
   Google Scholar
• HARVEY KB, BOTHE A, BLACKBURN GL: Nutritional assessment and patient outcome during oncological therapy. Cancer (1979) 43:2065-2069.
   PubMed Web of Science ®Google Scholar
• NIXON DW, HEYMSFIELD SB, COHEN AE et al.: Protein-caloric undernutrition in hospitalized cancer patients. Am. J. Med. (1980) 68:683-690.
   PubMed Web of Science ®Google Scholar
• DE WYS WD: Management of cancer cachexia. Semin. Oncol. (1985) 12:452-460.
   PubMed Web of Science ®Google Scholar
• ARGILÉ JM, GARCÍA-MARTÍNEZ C, LLOVERA M, LÓPEZ-SORIANO FJ: The role of cytokines in muscle wasting: its relation with cancer cachexia. Med. Res. Rev. (1992) 12:637-652.
   PubMed Web of Science ®Google Scholar
• ADAMS R, VICTOR M: In asthenia. In: Principles of Neurology. Adams R, Victor M (Eds), McGraw-Hill, New York (1981):341-345.
   Google Scholar
• ARGILÉS JM, ALVAREZ B, LÓPEZ-SORIANO FJ: The metabolic basis of cancer cachexia. Med. Res. Rev. (1997) 17:477-498.
   PubMed Web of Science ®Google Scholar
• NG EH, LOWRY SF: Nutritional suport and cancer cachexia. Evolving concepts of mechanisms and adjunctive therapies. Hematol. Oncol. Clin. North Am. (1991) 5:161-184.
   PubMed Web of Science ®Google Scholar
• DEWYS WD, BEGG C, LAVIN PT et al.: Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern cooperative oncology group. Am. J. Med. (1980) 69:491-497.
   PubMed Web of Science ®Google Scholar
• LOPRINZI CL, MICHALAK JC, SCHAID DJ et al.: Phase III evaluation of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. J. Clin. Oncol. (1993) 11:762-767.
   PubMed Web of Science ®Google Scholar
• BRUERA E, MACMILLAN K, KUEHN N, HANSON J, MACDONALD RN: A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status and other symptoms in patients with advanced cancer. Cancer (1990) 66:1279-1282.
   PubMed Web of Science ®Google Scholar
• NERI B, GAROS VLI, INTINI C: Effect of medroxyprogesterone acetate on the quality of life of the oncologic patient: a multicentric cooperative study. Anticancer Drugs (1997) 8:459-465.
   PubMed Web of Science ®Google Scholar
• MCCARTHY H, CROWDER R, DRYDEN S, WILLIAMS G: Megestrol acetate stimulates food and water intake in the rat: effects on regional hypothalamic neuropeptide Y concentrations. Eur. J. Pharmacol. (1994) 265:99-102.
   PubMed Web of Science ®Google Scholar
• MANTOVANI G, MACCIO A, ESU S et al.: Medroxyprogesterone acetate reduces the in vitro production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells and cancer patients. Eur. J. Cancer (1997) 33:602-607.
   PubMedGoogle Scholar
• VON ROENN J, ARMSTRONG D, KOTLER DP et al.: Megestrol acetate in patients with AIDS-related cachexia. Ann. Intern. Med. (1994) 121:393-399.
   PubMed Web of Science ®Google Scholar
• LOPRINZI CL, SCHAID DJ, DOSE AM, BURNHAM NL, JENSEN MD: Body-composition changes in patients who gain weight while receiving megestrol acetate. J. Clin. Oncol. (1993) 11:152-154.
   PubMed Web of Science ®Google Scholar
• TOMÍSKA M, TOMISKOVÁ M, SALAJKA F, ADAM Z, VORLÍCEK J: Palliative treatment of cancer anorexia with oral suspension of megestrol acetate. Neoplasma (2003) 50:227-233.
   PubMed Web of Science ®Google Scholar
• HOHMANN AG, SUPLITA RL II: Endocannabinoid mechanisms of pain modulation. AAPS J. (2006) 8:E693-E708.
   PubMed Web of Science ®Google Scholar
• PLASSE TF, GORTER RW, KRASNOW SH, LANE M, SHEPHARD KY, WADLEIGH RG: Recent clinical experience with dronabinol. Pharmacol. Biochem. Behav. (1991) 40:695-700.
   PubMed Web of Science ®Google Scholar
• MITCHELSON F: Pharmacological agents affecting emesis: a review. Drugs (1992) 43:295-315.
   PubMed Web of Science ®Google Scholar
• WATZL B, SCUDERI P, WATSON RR: Marijuana components stimulate peripheral blood mononuclear cell secretion of interferon-γ and suppress interleukin-1-α in vitro. Int. J. Immunopharmacol. (1991) 13:1091-1097.
   PubMed Web of Science ®Google Scholar
• SRIVASTAVA MD, SRIVASTAVA BI, BROUHARD B: Δ9-Tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. Immunopharmacology (1998) 40:179-185.
   PubMed Web of Science ®Google Scholar
• FACCHINETTI F, DEL GIUDICE E, FUREGATO S, PASSAROTTO M, LEON A: Cannabinoids ablate release of TNFα in rat microglial cells stimulated with lypopolysaccharide. Glia (2003) 41:161-168.
   PubMed Web of Science ®Google Scholar
• SALLAN SE, CRONIN C, ZELEN M, ZINBERG NE: Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of Δ-9-tetrahydrocannabinoid and prochlorperazine. N. Engl. J. Med. (1980) 302:135-138.
   PubMed Web of Science ®Google Scholar
• STRASSER F, LUFTNER D, POSSINGER K et al.: Comparison of orally administered Cannabis extract and Δ-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, Phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-in-cachexia-study-group. J. Clin. Oncol. (2006) 24:3394-3400.
   PubMed Web of Science ®Google Scholar
• ROSSI-FANELLI F, CANGIANO C: Increased availability of tryptophan in brain as a common pathogenic mechanism for anorexia associated with different diseases. Nutrition (1991) 7:364-367.
   PubMed Web of Science ®Google Scholar
• LAVIANO A, MEGUID MM, YANG ZJ, GLEASON JR, CANGIANO C, ROSSI-FANELLI F: Cracking the riddle of cancer anorexia. Nutrition (1996) 12:706-710.
   PubMed Web of Science ®Google Scholar
• KARDINAL CG, LOPRINZI CL, SCHAID DJ et al.: A controlled trial of cyproheptadine in cancer patients with anorexia. Cancer (1990) 65:2657-2662.
   PubMed Web of Science ®Google Scholar
• MOLEY JF, MORRISON FD, NORTON JA: Preoperative insulin reverses cachexia and decreases mortality in tumor-bearing rats. J. Surg. Res. (1987) 43:21-28.
   PubMed Web of Science ®Google Scholar
• TESSITORE L, COSTELLI P, BACCINO FM: Humoral mediation for cachexia in tumor-bearing rats. Br. J. Cancer (1993) 67:15-23.
   PubMed Web of Science ®Google Scholar
• MOLEY JF, MORRISON SD, GORSCHBOTH CM, NORTON JA: Body composition changes in rats with experimental cachexia: improvements with exogenous insulin. Cancer Res. (1988) 48:2784-2787.
   PubMed Web of Science ®Google Scholar
• BECK SA, TISDALE MJ: Effect of insulin on weight loss and tumour growth in a cachexia model. Br. J. Cancer (1989) 59:677-681.
   PubMed Web of Science ®Google Scholar
• VIGANO A, WATANABE S, BRUERA E: Anorexia and cachexia in advanced cancer patients. Cancer Surv. (1994) 21:99-115.
   PubMedGoogle Scholar
• DEROGATIS L, MACDONALD R: Psychopharmacologic applications to cancer. Cancer (1982) 50:968-1973.
   Google Scholar
• LÓPEZ-SORIANO J, CARBÓ N, LÓPEZ-SORIANO FJ et al.: Leptin and tumour growth in the rat. Int. J. Cancer (1999) 81:726-729.
   PubMed Web of Science ®Google Scholar
• ALEMAN MR, SANTOLARIA F, BATISTA N et al.: Leptin role in advanced lung cancer. A mediator of the acute phase response or a marker of the status of nutrition? Cytokine (2002) 19:21-26.
   PubMed Web of Science ®Google Scholar
• ARPACI F, YILMAZ MI, OZET A et al.: Low serum leptin level in colon cancer patients without significant weight loss. Tumori (2002) 88:147-149.
   PubMed Web of Science ®Google Scholar
• SHIMIZU Y, NAGAYA N, ISOBE T et al.: Increased plasma ghrelin level in lung cancer cachexia. Clin. Cancer Res. (2003) 9:774-778.
   PubMed Web of Science ®Google Scholar
• INUI A, MEGUID MM: Ghrelin and cachexia. Diabetes Obes. Metab. (2002) 4:431.
   PubMed Web of Science ®Google Scholar
• NAGAYA N, KANGAWA K: Ghrelin improves left ventricular dysfunction and cardiac cachexia in heart failure. Curr. Opin. Pharmacol. (2003) 3:146-151.
   PubMed Web of Science ®Google Scholar
• NAGAYA N, UEMATSU M, KOJIMA M et al.: Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation (2001) 104:1430-1435.
   PubMed Web of Science ®Google Scholar
• HANADA T, TOSHINAI K, KAJIMURA N et al.: Anti-cachectic effect of ghrelin in nude mice bearing human melanoma cells. Biochem. Biophys. Res. Commun. (2003) 301:275-279.
   PubMed Web of Science ®Google Scholar
• NEARY NM, SMALL CJ, WREN AM et al.: Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J. Clin. Endocrinol. Metab. (2004) 89:2832-2836.
   PubMed Web of Science ®Google Scholar
• WYNNE K, GIANNITSOPOULOU K, SMALL CJ et al.: Subcutaneous ghrelin enhances acute food intake in malnourished patients who receive maintenance peritoneal dialysis: a randomized, placebo-controlled trial. J. Am. Soc. Nephrol. (2005) 16(7):2111-2118.
   PubMed Web of Science ®Google Scholar
• SHIMIZU H, INOUE K, MORI M: The leptin-dependent and -independent melanocortin signaling system: regulation of feeding and energy expenditure. J. Endocrinol. (2007) 193:1-9.
   PubMed Web of Science ®Google Scholar
• SCARLETT JM, MARKS DL: The use of melanocortin antagonists in cachexia of chronic disease. Expert Opin. Investig. Drugs (2005) 14:1233-1239.
   PubMed Web of Science ®Google Scholar
• DEBOER MD, MARKS DL: Therapy insight: use of melanocortin antagonists in the treatment of cachexia in chronic disease. Nat. Clin. Pract. Endocrinol. Metab. (2006) 2:459-466.
   PubMedGoogle Scholar
• RAVASCO P, MONTEIRO GRILLO I, CAMILO M: Cancer wasting and quality of life react to early individualized nutritional counselling! Clin. Nutr. (2007) 26:7-15.
   PubMed Web of Science ®Google Scholar
• BOZZETTI F, AMMATUNA M, MIGLIAVACA S et al.: Total parenteral nutrition prevents further nutritional deterioration in patients with cancer cachexia. Ann. Surg. (1987) 205:138-143.
   PubMed Web of Science ®Google Scholar
• MULLER JM, BRENNER U, DIENST C, PICHLMAIER H: Preoperative parenteral feeding in patients with gastrointestinal cancer. Lancet (1982) 1:68-71.
   PubMed Web of Science ®Google Scholar
• KLEIN S, SIMES J, BLACKBURN GL: Total parenteral nutrition and cancer clinical trials. Cancer (1986) 58:1378-1386.
   PubMed Web of Science ®Google Scholar
• EVANS RD, ARGILÉS JM, WILLIAMSON DH: Metabolic effects of TNF-α (cachectin) and interleukin-1. Clin. Sci. (1989) 77:357-364.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO N, KAWAMURA I, NISHIGAKI F et al.: Effect of FR143430, a novel cytokine suppressive agent, on adenocarcinoma colon-26-induced cachexia in mice. Anticancer Res. (1998) 18:139-144.
   PubMed Web of Science ®Google Scholar
• BALAZS C, KISS E: Immunological aspects of the effect of pentoxifylline (trental). Acta Microbiol. Immunol. Hung. (1994) 41:121-126.
   PubMedGoogle Scholar
• GOLDBERG RM, LOPRINZI CL, MAILLIARD JA et al.: Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. J. Clin. Oncol. (1995) 13:2856-2859.
   PubMed Web of Science ®Google Scholar
• SAMPAIO EP, SARNO EN, GALILLY R, COHN ZA, KAPLAN G: Thalidomide selectively inhibits TNF-α production in stimulated human monocytes. J. Exp. Med. (1991) 173:699-703.
   PubMed Web of Science ®Google Scholar
• SAMPAIO EP, KAPLAN G, MIRANDA A et al.: The infuence of thalidomide on the clinical and immunological manifestation of erithema nodosum leprosum. J. Infect. Dis. (1993) 168:408-414.
   PubMed Web of Science ®Google Scholar
• MOREIRA AL, SAMPAIO EP, ZMUIDZINAS A, FRINDT P, SMITH KA, KAPLAN GJ: Thalidomide exerts its inhibitory action on TNF-α by enhancing mRNA degradation. Exp. Med. (1993) 177:1675-1680.
   PubMed Web of Science ®Google Scholar
• TRAMONTANA JM, UTAIPAT U, MOLLOY A et al.: Thalidomide treatment reduces TNF-α production and enhances weight gain in patients with pulmonary tuberculosis. Mol. Med. (1995) 1:384-397.
   PubMed Web of Science ®Google Scholar
• BRUERA E, NEUMANN CM, PITUSKIN E, CALDER K, BALL G, HANSON J: Thalidomide in patients with cachexia due to terminal cancer: preliminary report. Ann. Oncol. (1999) 10:857-859.
   PubMed Web of Science ®Google Scholar
• KHAN ZH, SIMPSON EJ, COLE AT et al.: Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass. Aliment. Pharmacol. Ther. (2003) 17:677-682.
   PubMed Web of Science ®Google Scholar
• GORDON JN, TREBBLE TM, ELLIS RD, DUNCAN HD, JOHNS T, GOGGIN PM: Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut (2005) 54:540-545.
   PubMed Web of Science ®Google Scholar
• CARBÓ N, COSTELLI P, TESSITORE L et al.: Anti-TNF-α treatment interferes with changes in lipid metabolism in a tumour cachexia model. Clin. Sci. (1994) 87:349-355.
   PubMed Web of Science ®Google Scholar
• COSTELLI P, CARBÓ N, TESSITORE L et al.: TNF-α mediates changes in tissue protein turnover in a rat cancer cachexia model. J. Clin. Invest. (1993) 92:2783-2789.
   PubMed Web of Science ®Google Scholar
• REINHART K, WIEGAND-LOHNERT C, GRIMMINGER F et al.: Assessment of the safety and eficacy of the monoclonal anti-TNF antibody fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit. Care Med. (1996) 24:733-742.
   PubMed Web of Science ®Google Scholar
• JATOI A, DAKHIL SR, NGUYEN PL et al.: A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North central cancer treatment group. Cancer (2007) 110:1396-1403.
   PubMed Web of Science ®Google Scholar
• YASUMOTO K, MUKAIDA N, HARADA A et al.: Molecular analysis of the cytokine network involved in cachexia in colon 26 adenocarcinoma-bearing mice. Cancer Res. (1995) 55:921-927.
   PubMed Web of Science ®Google Scholar
• STRASSMANN G, FONG M, FRETER CE et al.: Suramin interfers with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo. J. Clin. Invest. (1993) 92:2152-2159.
   PubMed Web of Science ®Google Scholar
• MATTHYS P, HEREMANS H, OPDENAKKER G et al.: Anti-interferon-γ antibody treatment, growth of Lewis lung tumours in mice and tumour-associated cachexia. Eur. J. Cancer (1991) 27:182-187.
   PubMed Web of Science ®Google Scholar
• COSTELLI P, LLOVERA M, CARBÓ N, GARCIA-MARTINEZ C, LOPEZ-SORIANO FJ, Argiles JM: Interleukin-1 receptor antagonist (IL-1ra) is unable to reverse cachexia in rats bearing an ascites hepatoma (Yoshida AH-130). Cancer Lett. (1995) 95:33-38.
   PubMed Web of Science ®Google Scholar
• ANKER SD, COATS AJ: How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int. J. Cardiol. (2002) 86:123-130.
   PubMed Web of Science ®Google Scholar
• MONK JP, PHILLIPS G, WAITE R et al.: Assessment of TNF-α blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. J. Clin. Oncol. (2006) 24:1852-1859.
   PubMed Web of Science ®Google Scholar
• MORI K, FUJIMOTO-OUCHI K, ISHIKAWA T, SEKIGUCHI F, ISHITSUKA H, TANAKA Y: Murine interleukin-12 prevents the development of cancer cachexia in a murine model. Int. J. Cancer (1996) 67:849-855.
   PubMed Web of Science ®Google Scholar
• TANAKA Y, EDA H, TANAKA T et al.: Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice. Cancer Res. (1990) 50:2290-2295.
   PubMed Web of Science ®Google Scholar
• FUJIMOTO-OUCHI K, TAMURA S, MORI K, TANAKA Y, ISHITSUKA H: Establishment and characterization of cachexia inducing and non-inducing clones of murine colon 26 carcinoma. Int. J. Cancer (1995) 61:522-528.
   PubMed Web of Science ®Google Scholar
• BIELEFELDT-OHMANN H, MARZO AL, HIMBECK RP, JARNICKI AG, ROBINSON BW, FITZPATRICK DR: Interleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon-γ immunotherapy. Cancer Immunol. Immunother. (1995) 40:241-250.
   PubMed Web of Science ®Google Scholar
• QUINN LS, HAUGK KL, GRABSTEIN KH: Interleukin-15: a novel anabolic cytokine for skeletal muscle. Endocrinology (1995) 136:3669-3672.
   PubMed Web of Science ®Google Scholar
• CARBO N, LOPEZ-SORIANO J, COSTELLI P et al.: Interleukin-15 antagonizes muscle protein waste in tumour-bearing rats. Br. J. Cancer (2000) 83:526-531.
   PubMed Web of Science ®Google Scholar
• CARBÓ N, LÓPEZ-SORIANO J, COSTELLI P et al.: Interleukin-15 mediates reciprocal regulation of adipose and muscle mass: a potential role in body weight control. Biochim. Biophys. Acta (2001) 1526:17-24.
   PubMed Web of Science ®Google Scholar
• FIGUERAS M, BUSQUETS S, CARBÓ N et al.: Interleukin-15 is able to suppress the increased DNA fragmentation associated with muscle wasting in tumour-bearing rats. FEBS Lett. (2004) 569:201-206.
   PubMed Web of Science ®Google Scholar
• BUSQUETS S, FIGUERAS M, MEIJSING S et al.: Interleukin-15 decreases proteolysis in skeletal muscle: a direct effect. Int. J. Mol. Med. (2005) 16:471-476.
   PubMed Web of Science ®Google Scholar
• WOLF RF, HESLIN MJ, NEWMAN E, PEARLSTONE DB, GONENNE A, BRENNAN MF: Growth hormone and insulin combine to improve whole-body and skeletal protein kinetics. Surgery (1992) 112:284-291.
   PubMed Web of Science ®Google Scholar
• FRYBURG DA, GELFAND RA, BARRETT EJ: Growth hormone acutely stimulates forearm muscle protein synthesis in normal humans. Am. J. Physiol. (1991) 260:E499-E504.
   PubMed Web of Science ®Google Scholar
• MANSON JM, SMITH RJ, WILMORE DW: Growth hormone stimulates protein synthesis during hypocaloric parenteral nutrition. Ann. Surg. (1988) 208:136-142.
   PubMed Web of Science ®Google Scholar
• WOLF RF, PEARLSTONE DB, NEWMAN E et al.: Growth hormone and insulin reverse net whole-body and skeletal muscle protein catabolism in cancer patients. Ann. Surg. (1992) 216:280-290.
   PubMed Web of Science ®Google Scholar
• NG B, WOLF RF, WEKSLER B, BRENNAN MF, BURT M: Growth hormone administration preserves lean body mass in sarcoma-bearing rats treated with doxorubicin. Cancer Res. (1993) 53:5483-5486.
   PubMed Web of Science ®Google Scholar
• FROESCH ER, SCHMID C, SCHWANDER J, ZAPF J: Actions of insulin-like growth factors. Annu. Rev. Physiol. (1985) 47:443-467.
   PubMed Web of Science ®Google Scholar
• FLORINI J: Hormonal control of muscle growth. Muscle Nerve (1987) 10:577-598.
   PubMed Web of Science ®Google Scholar
• FLORINI JR, EWTON DZ, COOLICAN SA: Growth hormone and the insulin-like factor system in myogenesis. Endocr. Rev. (1996) 17:481-517.
   PubMed Web of Science ®Google Scholar
• DAHN M, LANGE P, JACOBS L: Insulin-like growth factor I production is inhibited in human sepsis. Arch. Surg. (1988) 123:1409-1414.
   PubMed Web of Science ®Google Scholar
• NG EH, ROCK CS, LAZARUS DD, STIAINO-COICO L, MOLDAWER LL, LOWRY SF: Insulin-like growth factor I preserves host lean tissue mass in cancer cachexia. Am. J. Physiol. (1992) 262:R426-R431.
   PubMed Web of Science ®Google Scholar
• ROSENTHAL N, MUSARO A: Gene therapy for cardiac cachexia? Int. J. Cardiol. (2002) 85:185-191.
   PubMed Web of Science ®Google Scholar
• LISSONI P, BARNI S, TANCINI G et al.: Role of the pineal gland in the control of macrophage functions and its possible implication in cancer: a study of interactions between TNF-α and the pineal hormone melatonin. J. Biol. Regul. Homeost. Agents (1994) 8:126-129.
   PubMed Web of Science ®Google Scholar
• LISSONI P, PAOLOROSSI F, TANCINI G et al.: Is there a role for melatonin in the treatment of neoplastic cachexia? Eur. J. Cancer (1996) 32A:1340-1343.
   PubMed Web of Science ®Google Scholar
• LISSONI P, PAOLOROSSI F, ARDIZZOIA A et al.: A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state. J. Pineal Res. (1997) 23:15-19.
   PubMed Web of Science ®Google Scholar
• BARTLETT DL, CHARLAND S, TOROSIAN MH: Growth hormone, insulin, and somatostatin therapy of cancer cachexia. Cancer (1994) 73:1499-1504.
   PubMed Web of Science ®Google Scholar
• PATTON JS, SHEPARD HM, WILKING H et al.: Interferons and TNF have similar catabolic effects on 3T3L1 cells. Proc. Natl. Acad. Sci. USA (1986) 83:8313-8317.
   PubMed Web of Science ®Google Scholar
• BOUGHTON B: Drug increases lean tissue mass in patients with cancer. Lancet Oncol. (2003) 4:135.
   PubMed Web of Science ®Google Scholar
• COSTELLI P, GARCIA-MARTINEZ C, LLOVERA M et al.: Muscle protein waste in tumor-bearing rats is effectively antagonized by a β2-adrenergic agonist (clenbuterol). J. Clin. Invest. (1995) 95:2367-2372.
   PubMed Web of Science ®Google Scholar
• CARBO N, LOPEZ-SORIANO J, TARRAGO T et al.: Comparative effects of β2-adrenergic agonists on muscle waste associated with tumour growth. Cancer Lett. (1997) 115:113-118.
   PubMed Web of Science ®Google Scholar
• COSTELLI P, LLOVERA M, GARCIA-MARTINEZ C, CARBO N, LOPEZ-SORIANO FJ, ARGILES JM: Enhanced leucine oxidation in rats bearing an ascites hepatoma (Yoshida AH-130) and its reversal by clenbuterol. Cancer Lett. (1995) 91:73-78.
   PubMed Web of Science ®Google Scholar
• BUSQUETS S, FIGUERAS M, FUSTER G et al.: Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting. Cancer Res. (2004) 64:6725-6731.
   PubMed Web of Science ®Google Scholar
• ANTI M, MARRA G, ARMELAO F et al.: Effect of Ω-3 fatty acids on rectal mucosal cell proliferation in subjects at risk for colon cancer. Gastroenterology (1992) 103:883-891.
   PubMed Web of Science ®Google Scholar
• ROSE DP, CONNOLLY JM: Effects of dietary Ω-3 fatty acids on human breast cancer growth and metastases in nude mice. J. Natl. Cancer Inst. (1993) 85:1743-1747.
   PubMed Web of Science ®Google Scholar
• TISDALE MJ: Mechanism of lipid mobilization associated with cancer cachexia: interaction between the polyunsaturated fatty acid, eicosapentaenoic acid, and inhibitory guanine nucleotide-regulatory protein. Prostagl. Leukotr. Essen. Fatty Acids (1993) 48:105-109.
   PubMed Web of Science ®Google Scholar
• BECK SA, SMITH KL, TISDALE MJ: Anticachectic and antitumour effect of eicosapentaenoic acid and its effect on protein turnover. Cancer Res. (1991) 51:6089-6093.
   PubMed Web of Science ®Google Scholar
• COSTELLI P, LLOVERA M, LOPEZ-SORIANO J et al.: Lack of effect of eicosapentaenoic acid in preventing cancer cachexia and inhibiting tumour growth. Cancer Lett. (1995) 97:25-32.
   PubMed Web of Science ®Google Scholar
• WIGMORE SJ, ROSS JA, FALCONER JS et al.: The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. Nutrition (1996) 12:S27-S30.
   PubMed Web of Science ®Google Scholar
• FEARON KC, VON MEYENFELDT MF, MOSES AG et al.: Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut (2003) 52:1479-1486.
   PubMed Web of Science ®Google Scholar
• FEARON KC, BARBER MD, MOSES AG et al.: Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J. Clin. Oncol. (2006) 24:3401-3407.
   PubMed Web of Science ®Google Scholar
• TAYEK JA, BISTRIAN BR, HEHIR DJ, MARTIN R, MOLDAWER LL, BLACKBURN GL: Improved protein kinetics and albumin synthesis by branched-chain amino acid-enriched total parenteral nutriton in cancer cachexia. Cancer (1986) 58:147-157.
   PubMed Web of Science ®Google Scholar
• HUNTER DC, WEINTRAUB M, BLACKBURN GL, BISTRIAN BR: Branched-chain amino acids as the protein component of parenteral nutrition in cancer cachexia. Br. J. Surg. (1989) 76:149-153.
   PubMed Web of Science ®Google Scholar
• CANGIANO C, LAVIANO A, MEGUID MM et al.: Effects of administration of oral branched-chain amino acids on anorexia and caloric intake in cancer patients. J. Natl. Cancer Inst. (1996) 88:550-552.
   PubMed Web of Science ®Google Scholar
• BUSQUETS S, ALVAREZ B, LLOVERA M et al.: Branched-chain amino acids inhibit proteolysis in rat skeletal muscle: mechanisms involved. J. Cell Physiol. (2000) 184:380-384.
   PubMed Web of Science ®Google Scholar
• BUSQUETS S, ALVAREZ B, LOPEZ-SORIANO FJ, ARGILES JM.: Branched-chain amino acids: a role in skeletal muscle proteolysis in catabolic states? J. Cell Physiol. (2002) 191:283-289.
   PubMed Web of Science ®Google Scholar
• KRAUSE R, JAMES JH, ZIPARO V, FISCHER JE: Brain tryptophan and the neoplastic anorexia/cachexia syndrome. Cancer (1979) 44:1003-1008.
   PubMed Web of Science ®Google Scholar
• MEGUID MM, MUSCARITOLI M, BEVERLY JL, YANG ZJ, CANGIANO C, ROSSI-FANELLI F: The early cancer anorexia paradigm: changes in plasma free tryptophan and feeding indexes. J. Parent. Enteral. Nutr. (1992) 16(6 Suppl.):S56-S59.
   PubMed Web of Science ®Google Scholar
• FERNSTROM JD: Dietary effects on brain serotonin synthesis: relationship to appetite regulation. Am. J. Clin. Nutr. (1985) 42:1072-1082.
   PubMed Web of Science ®Google Scholar
• SOUBA WW: Glutamine and cancer. Ann. Surg. (1993) 218:715-728.
   PubMed Web of Science ®Google Scholar
• RIVERA S, AZCON-BIETO J, LOPEZ-SORIANO FJ, MIRALPEIX M, ARGILES JM: Amino acid metabolism in tumour-bearing mice. Biochem. J. (1988) 249:443-449.
   PubMed Web of Science ®Google Scholar
• CHEN MK, SALLOUM RM, AUSTGEN T et al.: Tumor regulation of hepatic glutamine metabolism. J. Parent. Enteral. Nutr. (1991) 15:159-164.
   PubMed Web of Science ®Google Scholar
• ZIEGLER TR, YOUNG LS, BENFELL K et al.: Clinical and metabolic efficacy of glutamine-supplemented parenteral nutrition after bone marrow transplantation. Ann. Intern. Med. (1992) 116:821-828.
   PubMed Web of Science ®Google Scholar
• KLIMBERG VS, NWOKEDI E, HUTCHINS LF et al.: Glutamine facilitates chemotherapy while reducing toxicity. J. Parent. Enteral. Nutr. (1992) 16:S83-S87.
   PubMed Web of Science ®Google Scholar
• LAVIANO A, RENVYLE T, YANG ZJ: From laboratory to bedside: new strategies in the treatment of malnutrition in cancer patients. Nutrition (1996) 12:112-122.
   PubMed Web of Science ®Google Scholar
• DROGE W, GROSS A, HACK V et al.: Role of cysteine and glutathione in HIV infection and cancer cachexia: therapeutic intervention with N-acetylcysteine. Adv. Pharmacol. (1996) 38:581-600.
   Google Scholar
• TAYEK JA: A review of cancer cachexia and abnormal glucose metabolism in humans with cancer. J. Am. Coll. Nutr. (1992) 11:445-456.
   PubMed Web of Science ®Google Scholar
• HACK V, GROSS A, KINSCHERF R et al.: Abnormal glutathione and sulfate levels after interleukin-6 treatment in tumor-induced cachexia. FASEB J. (1996) 10:1219-1226.
   PubMedGoogle Scholar
• VAN BUREN CT, RUDOLPH FB, KULKARNI A, PIZZINI R, FANSLOW WC, KUMAR S: Reversal of immunosuppression induced by a protein-free diet: comparison of nucleotides, fish oil, and arginine. Crit. Care Med. (1990) 18:S114-S117.
   PubMed Web of Science ®Google Scholar
• GOLD J: Use of hydrazine sulphate in terminal and pre-terminal cancer patients: results of investigation of new drug (IND) study in 84 evaluable patients. Oncology (1975) 32:1-10.
   PubMed Web of Science ®Google Scholar
• CHLEBOWSKI RT, BULCAVAGE L, GROSVENOR M et al.: Hydrazine sulphate influence of nutritional status and survival in non-small cell lung cancer. J. Clin. Oncol. (1990) 8:9-15.
   PubMed Web of Science ®Google Scholar
• TAYEK JA, HEBER D, CHLEBOWSKI RT: Effective hydrazine sulphate on whole-body protein breakdown measured by 14C-lysine metabolism in lung cancer patients. Lancet (1987) 2:241-244.
   PubMed Web of Science ®Google Scholar
• KIKAWA Y, NARUMIYA S, FUKUSHIMA M, WAKATSUKA H, HAYAISHI O: 9-Deoxy-Δ9, Δ12 – 13,14 dihydroprostaglandin D2, a metabolite of prostaglandin D2 formed in human placenta. Proc. Natl. Acad. Sci. USA (1984) 81:1317-1321.
   PubMed Web of Science ®Google Scholar
• FISCHER SM, FURSTENBERGER G, MARKS F, SLAGA TJ: Events associated with mouse skin tumor promotion with respect to arachidonic acid metabolism: a comparison between SENCAR and NMRI mice. Cancer Res. (1987) 47:3174-3179.
   PubMed Web of Science ®Google Scholar
• BENNETT A, HOUGHTON J, LEAPER DJ, STAMFORD IF: Cancer growth, response to treatment and survival time in mice: beneficial effect of the prostaglandin synthesis inhibitor flurbiprofen. Prostaglandins (1979) 17:179-191.
   PubMedGoogle Scholar
• WILLIAMS ED, KARIM SMM, SANDLER M: Prostaglandin secretion by medullary carcinoma of the thyroid. A possible cause of the associated diarrhoea. Lancet (1968) 1:22-23.
   PubMed Web of Science ®Google Scholar
• HOMEM-DE-BITTENCOURT JUNIOR PI, PONTIERI V, CURI RR, LOPES OU: Effects of aspirin-like drugs on Walker 256 tumor growth and cachexia in rats. Braz. J. Med. Biol. Res. (1989) 22:1039-1042.
   PubMed Web of Science ®Google Scholar
• MCCARTHY DO, DAUN JM: The effects of cyclooxigenase inhibitors on tumor-induced anorexia in rats. Cancer (1993) 71:486-492.
   PubMed Web of Science ®Google Scholar
• HUSSEY HJ, TISDALE MJ: Effect of the specific cyclooxygenase-2 inhibitor meloxicam on tumour growth and cachexia in a murine model. Int. J. Cancer (2000) 87:95-100.
   PubMed Web of Science ®Google Scholar
• CAHLIN C, GELIN J, DELBRO D, LONNROTH C, DOI C, LUNDHOLM K: Effect of cyclooxygenase and nitric oxide synthase inhibitors on tumor growth in mouse tumor models with and without cancer cachexia related to prostanoids. Cancer Res. (2000) 60:1742-1749.
   PubMed Web of Science ®Google Scholar
• DANERYD P: Epoetin α for protection of metabolic and exercise capacity in cancer patients. Semin. Oncol. (2002) 29:69-74.
   PubMed Web of Science ®Google Scholar
• MANTOVANI G, GHIANI M, CURRELI L et al.: Assessment of the efficacy of two dosages and schedules of human recombinant erythropoietin in the prevention and correction of cisplatin-induced anemia in cancer patients. Oncol. Rep. (1999) 6:421-426.
   PubMed Web of Science ®Google Scholar
• DANERYD P, SVANBERG E, KORNER U et al.: Protection of metabolic and exercise capacity in unselected weight-losing cancer patients following treatment with recombinant erythropoietin: a randomized prospective study. Cancer Res. (1998) 58:5374-5379.
   PubMed Web of Science ®Google Scholar
• LINDHOLM E, DANERYD P, KÖRNER U, HYLTANDER A, FOULADIUN M, LUNDHOLM K: Effects of recombinant erythropoietin in palliative treatment of unselected cancer patients. Clin. Cancer Res. (2004) 10:6855-6864.
   PubMed Web of Science ®Google Scholar
• KANZAKI M, SODA K, GIN PT, KAI T, KONISHI F, KAWAKAMI M: Erythropoietin attenuates cachectic events and decreases production of interleukin-6, a cachexia-inducing cytokine. Cytokine (2005) 32:234-239.
   PubMed Web of Science ®Google Scholar
• HASKELL CM, MENDOZA E, PISTERS KM, FOSSELLA FV, FIGLIN RA: Phase II study of intravenous adenosine 5′-triphosphate in patients with previously untreated stage IIIB and stage IV non-small cell lung cancer. Invest. New Drugs (1998) 16:81-85.
   PubMed Web of Science ®Google Scholar
• AGTERESCH HJ, DAGNELIE PC, VAN DER GAAST A, STIJNEN T, WILSON JH: Randomized clinical trial of adenosine 5′-triphosphate in patients with advanced non-small-cell lung cancer. J. Natl. Cancer Inst. (2000) 92:321-328.
   PubMed Web of Science ®Google Scholar
• AGTERESCH HJ, RIETVELD T, KERKHOFS LG, VAN DEN BERG JW, WILSON JH, DAGNELIE PC: Beneficial effects of adenosine triphosphate on nutritional status in advanced lung cancer patients: a randomized clinical trial. J. Clin. Oncol. (2002) 20:371-378.
   PubMed Web of Science ®Google Scholar
• ISHITSUKA H, MIWA M, TAKEMOTO K, FUKUOKA K, ITOGA A, MARUYAMA HB: Role of uridine phosphorylase for antitumor activity of 5′-deoxy-5-fluorouridine. Gann (1980) 71:112-123.
   PubMedGoogle Scholar
• KONO A, HARA Y, SUGATA S, KARUBE Y, MATSUSHIMA Y, ISHITSUKA H: Activation of 5′-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors. Chem. Pharm. Bull. (1983) 31:175-178.
   PubMed Web of Science ®Google Scholar
• TANAKA Y, EDA H, FUJIMOTO K, TANAKA T, ISHIKAWA T, ISHITSUKA H: Anticachectic activity of 5′-deoxy-5-fluorouridine in a murine tumor cachexia model, colon 26 adenocarcinoma. Cancer Res. (1990) 50:4528-4532.
   PubMed Web of Science ®Google Scholar
• EDA H, TANAKA Y, ISHITSUKA H: 5′Deoxy-5-fluorouridine improves cachexia by a mechanism independent of its antiproliferative action in colon 26 adenocarcinoma-bearing mice. Cancer Chemother. Pharmacol. (1991) 29:1-6.
   PubMed Web of Science ®Google Scholar
• LEE DH, GOLDBERG AL: Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell. Biol. (1998) 8:397-403.
   PubMed Web of Science ®Google Scholar
• VON HAEHLING S, GENTH-ZOTZ S, ANKER SD, VOLK HD: Cachexia: a therapeutic approach beyond cytokine antagonism. Int. J. Cardiol. (2002) 85:173-183.
   PubMed Web of Science ®Google Scholar
• BODINE SC, LATRES E, BAUMHUETER S et al.: Identification of ubiquitin ligases required for skeletal muscle atrophy. Science (2001) 294:1704-1708.
   PubMed Web of Science ®Google Scholar
• SANDERS PM, RUSSELL ST, TISDALE MJ: Angiotensin II directly induces muscle protein catabolism through the ubiquitin-proteasome proteolytic pathway and may play a role in cancer cachexia. Br. J. Cancer (2005) 93:425-434.
   PubMed Web of Science ®Google Scholar
• MCFARLANE C, PLUMMER E, THOMAS M et al.: Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-κB-independent, FoxO1-dependent mechanism. J. Cell Physiol. (2006) 209:501-514.
   PubMed Web of Science ®Google Scholar
• ISFORT RJ, WANG F, TSCHEINER M et al.: Discovery of corticotropin releasing factor 2 receptor selective sauvagine analogues for treatment of skeletal muscle atrophy. J. Med. Chem. (2005) 48:262-265.
   PubMed Web of Science ®Google Scholar
• ARGILÉS JM, FIGUERAS M, AMETLLER E et al.: Effects of CRF2R agonist on tumour growth and cachexia in mice bearing the lewis lung carcinoma. Muscle Nerve (2007):(In press).
   Google Scholar
• MANTOVANI G, MACCIÈ A, MADEDDU C et al.: A Phase II study showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress. Cancer Epidemiol. Biomarker. Prev. (2006) 15:1030-1034.
   PubMed Web of Science ®Google Scholar
• TEMEL JS, JACKSON VA, BILLINGS JA et al.: Phase II study: integrated palliative care in newly diagnosed advanced non-small-cell lung cancer patients. J. Clin. Oncol. (2007) 25:2377-2382.
   PubMed Web of Science ®Google Scholar